DrugPatentWatch Database Preview
Ariad Company Profile
Join the DrugPatentWatch Referral Program Get access to a free drug patent landscape report or a free one-month subscription
What is the competitive landscape for ARIAD, and when can generic versions of ARIAD drugs launch?
ARIAD has two approved drugs.
There are seven US patents protecting ARIAD drugs.
There are one hundred and twenty-two patent family members on ARIAD drugs in thirty-one countries and twenty-three supplementary protection certificates in fifteen countries.
Summary for Ariad
| International Patents: | 122 |
| US Patents: | 7 |
| Tradenames: | 2 |
| Ingredients: | 2 |
| NDAs: | 2 |
| Patent Litigation for Ariad: | See patent lawsuits for Ariad |
Drugs and US Patents for Ariad
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ariad | ALUNBRIG | brigatinib | TABLET;ORAL | 208772-001 | Apr 28, 2017 | RX | Yes | No | Start Trial | Start Trial | |||||
| Ariad | ALUNBRIG | brigatinib | TABLET;ORAL | 208772-001 | Apr 28, 2017 | RX | Yes | No | 10,385,078 | Start Trial | Y | Y | Start Trial | ||
| Ariad | ICLUSIG | ponatinib hydrochloride | TABLET;ORAL | 203469-003 | Apr 23, 2015 | RX | Yes | No | 8,114,874 | Start Trial | Y | Y | Start Trial | ||
| Ariad | ALUNBRIG | brigatinib | TABLET;ORAL | 208772-002 | Apr 28, 2017 | RX | Yes | No | 9,611,283 | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Ariad Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| South Korea | 101956261 | Start Trial |
| Eurasian Patent Organization | 200870515 | Start Trial |
| Slovenia | 1973545 | Start Trial |
| Poland | 2300013 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Ariad Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1973545 | C20130033 00093 | Estonia | Start Trial | PRODUCT NAME: PONATINIIB;REG NO/DATE: K(2013)4238 (LOPLIK) 01.07.2013 |
| 2300013 | 2019C/525 | Belgium | Start Trial | PRODUCT NAME: BRIGATINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT HIERVAN; AUTHORISATION NUMBER AND DATE: EU/1/18/1264 20181126 |
| 1973545 | CA 2013 00066 | Denmark | Start Trial | PRODUCT NAME: POATINIB, HERUNDER PONATINIB HYDROCHLORID; REG. NO/DATE: EU/1/13/839/001-004 20130701 |
| 1973545 | C01973545/01 | Switzerland | Start Trial | PRODUCT NAME: PONATINIBUM; REGISTRATION NO/DATE: SWISSMEDIC 63097 12.02.2014 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
